In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3401-3403

  Grossi, Olivier ^a   Caillon, Jocelyne ^a,b   Arvieux, Cedric ^a   Jacqueline, Cedric ^a   Bugnon, Denis ^a   Potel, Gilles ^a   Hamel, Antoine ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOXACILLIN; MOXIFLOXACIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; IN VIVO STUDY; INFECTIOUS ARTHRITIS; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, INFECTIOUS; AZA COMPOUNDS; CLOXACILLIN; COLONY COUNT, MICROBIAL; HALF-LIFE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; QUINOLINES; RABBITS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 35948979584     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01520-06     Document Type: Article

References (30)

1. Allen, G. P., G. W. Kaatz, and M. J. Rybak. 2004. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int. J. Antimicrob. Agents 24:150-160.
2. Amsterdam, D. 1996. Susceptibility testing of antibiotics in liquid media, p. 52-111. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, MD.
3. Andes, D. R., and W. A. Craig. 1998. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin. Infect. Dis. 27:47-50.
4. Black, J. T., T. L. Hunt, P. J. Godley, and E. Matthew. 1987. Oral antimicrobial therapy for adults with osteomyelitis or septic arthritis. J. Infect. Dis. 155:968-972.
5. Bugnon, D., G. Potel, J. Caillon, D. Baron, H. B. Drugeon, P. Feigel, and M. F. Kergueris. 1998. In vivo simulation of human pharmacokinetics in the rabbit. Bull. Math. Biol. 60:545-567.
6. Dan, M., O. Keynan, Z. Feldbrin, and F. Poch. 2004. Concentrations of moxifloxacin in serum and synovial fluid, and ex-vivo bacterial activity against arthritis-causing pathogens. Diagn. Microbiol. Infect. Dis. 48:283-286.
7. Dhawan, W. K., A. S. Bayer, and M. R. Yeaman. 2000. Thrombin-induced platelet microbicidal protein susceptibility phenotype influences the outcome of oxacillin prophylaxis and therapy of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 44:3206-3209.
8. Drancourt, M., A. Stein, J. N. Argenson, R. Roiron, P. Groulier, and D. Raoult. 1997. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J. Antimicrob. Chemother. 39:235-240.
9. Dubost, J. J., M. Soubrier, C. De Champs, J. M. Ristori, J. L. Bussière, and B. Sauvezie. 2002. No changes in the distribution of organisms responsible for septic arthritis over a 20-year period. Ann. Rheum. Dis. 61:267-269.
10. Entenza, J. M., Y. A. Que, J. Vouillamoz, M. P. Glauser, and P. Moreillon. 2001. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrob. Agents Chemother. 45:3076-3083.
11. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
12. Frippiat, F., F. Meunier, and G. Derue. 2004. Place of newer quinolones and rifampicin in the treatment of gram-positive bone and joint infections. J. Antimicrob. Chemother. 54:1158.
13. Gentry, L. O., and G. Rodriguez-Gomez. 1991. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob. Agents Chemother. 35:538-541.
14. Goldenberg, D. L. 1998. Septic arthritis. Lancet 351:197-202.
15. Gupta, M. N., R. D. Sturrock, and M. Field. 2001. A prospective 2-year study of 75 patients with adult-onset septic arthritis. Rheumatology 40:24-30.
16. Ince, D., X. Zhang, and D. C. Hooper. 2003. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1410-1415.
17. Johnson, A. H., W. G. Campbell, and B. C. Callahan. 1970. Infection of rabbit knee joints after intra-articular injection of Staphylococcus aureus. Comparison with joints infected with Staphylococcus albus. Am. J. Pathol. 60:165-203.
18. Lister, P. D. 2001. Pharmocodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin. Infect. Dis. 32(Suppl. 1):S33-S38.
19. MacGowan, A. P. 1999. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. Expert Opin. Investig. Drugs 8:181-199.
20. Mader, J. T., J. S. Cantrell, and J. Calhoun. 1990. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis. 1990. J. Bone Joint Surg. Am. 72:104-110.
21. Metzler, K., G. M. Hansen, P. Hedlin, E. Harding, K. Drlica, and J. M. Blondeau. 2004. Comparison of minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 24:161-167.
22. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, PA.
23. Rissing, J. P. 1997. Antimicrobial therapy for chronic osteomyelitis in adults: role of the fluoroquinolones. Clin. Infect. Dis. 25:1327-1333.
24. Shirliff, M. E., and T. J. Mader. 2002. Acute septic arthritis. Clin. Microbiol. Rev. 15:527-544.
25. Sierra, J. M., J. G. Cabeza, M. Ruiz Chaler, T. Montero, J. Hernandez, J. Menza, M. Llagostera, and J. Vila. 2005. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clin. Microbiol. Infect. 11:750-758.
26. Stass, H., and D. Kubitza. 1999. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J. Antimicrob. Chemother. 43(Suppl.B):83-90.
27. Sullivan, J. T., M. Woodruff, J. Lettieri, V. Agarwal, G. J. Krol, P. T. Leese, S. Watson, and A. H. Heller. 1999. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob. Agents Chemother. 43:2793-2797.
28. Weber, J. T. 2005. Community-associated methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 41(Suppl. 4):S269-S272.
29. Wise, R., J. M. Andrews, G. Marshall, and G. Hartman. 1999. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob. Agents Chemother. 43:1508-1510.
30. Xiong, Y. Q., G. Potel, J. Caillon, G. Stephant, F. Jehl, D. Bugnon, P. Le Conte, D. Baron, and H. Drugeon. 1995. Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:496-499.